FDA OKs Radius Health's osteoporosis med TYMLOS; shares up 11%

|About: Radius Health, Inc. (RDUS)|By:, SA News Editor

Radius Health (RDUS +10.5%) heads north on a 4x surge in volume in response to the FDA's approval of TYMLOS (abaloparatide) injection for the treatment of postmenopausal women with osteoporosis at high risk of fracture.

The company will host a webcast on Monday, May 1, at 7:30 am ET to discuss the approval.

Previously: Radius Health down 10% on delay of FDA action on abaloparatide (March 10)